Chemistry:Portmanteau inhibitor
From HandWiki
Revision as of 02:10, 30 June 2021 by imported>SpringEdit (fixing)
A portmanteau inhibitor is a drug that is a combination of two drug molecules, each of which is itself a type of inhibitor. The term was coined in 2007 by University of Minnesota researchers who designed and synthesized a combination HIV reverse transcriptase inhibitor and an integrase inhibitor,[1][2][3] and was further used in 2011 by a team of researchers combining an integrase inhibitor with a CCR5 entry inhibitor.[4]
Footnotes
- ↑ "U of M researchers announce advance in treatment of HIV". 25 July 2007. http://www.kare11.com/news/news_article.aspx?storyid=260376.
- ↑ "Researchers Discover New Method To Combat HIV". 25 July 2007. https://www.sciencedaily.com/releases/2007/07/070723160034.htm.
- ↑ Zhengqiang Wang; Eric M. Bennett; Daniel J. Wilson; Christine Salomon; Robert Vince (2007). "Rationally Designed Dual Inhibitors of HIV Reverse Transcriptase and Integrase". Journal of Medicinal Chemistry 50 (15): 3416–3419. doi:10.1021/jm070512p. PMID 17608468.
- ↑ Bodiwala, H. S.; Sabde, S.; Gupta, P.; Mukherjee, R.; Kumar, R.; Garg, P.; Bhutani, K. K.; Mitra, D. et al. (2011). "Design and synthesis of caffeoyl-anilides as portmanteau inhibitors of HIV-1 integrase and CCR5". Bioorganic & Medicinal Chemistry 19 (3): 1256–63. doi:10.1016/j.bmc.2010.12.031. PMID 21227704.
 |  |
